Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PrEP
Pharma
Gilead inks licensing deals to boost lenacapivir access
The company will allow six generic manufacturers to make and sell its long-acting PrEP drug, lenacapivir, in 120 resource-limited countries.
Zoey Becker
Oct 2, 2024 3:14pm
Gilead races toward filings for long-acting PrEP after trial win
Sep 12, 2024 11:45am
Gilead aims to shake up HIV PrEP market with long-acting launch
Aug 9, 2024 11:42am
What 'The Next Berlin Patient' means for HIV drug development
Aug 2, 2024 9:43am
US appeals Gilead's trial win in Truvada, Descovy patent fight
Jul 9, 2024 11:00am
Gilead’s twice-yearly PrEP drug shows 100% efficacy
Jun 20, 2024 11:45am